RORA Gene: Potential Drug Target Or Biomarker (G6095)

Target Name: RORA

NCBI ID: G6095

RORA

RORA Gene: Potential Drug Target Or Biomarker

RORA (Retinoid-related orphan receptor alpha) is a gene that has been identified as a potential drug target or biomarker for treating a variety of diseases, including cancer, obesity, and diabetes. The RORA gene is located on chromosome 1p36 and encodes a protein that is expressed in various tissues throughout the body.

History of the RORA gene

The RORA gene was first identified in the late 1990s as a potential gene that could be involved in the regulation of cell growth and differentiation. This was based on the fact that the gene was located near the breakpoint of a chromosomal translocation, which is a genetic event that can result in the fusion of two genes.

Following the identification of the RORA gene, researchers began to study its function in more detail. They found that the gene was involved in the regulation of cell growth, differentiation, and survival. They also found that the gene was expressed in a variety of tissues, including the brain, pancreas, and skin.

The potential drug target

The RORA gene has been identified as a potential drug target or biomarker because of its involvement in the regulation of cell growth and differentiation. This makes it an attractive target for drugs that are designed to inhibit cell growth or promote cell death.

One of the key reasons for the potential of the RORA gene as a drug target is its involvement in the regulation of cell survival. Studies have shown that RORA is involved in the regulation of cell survival by promoting the production of a protein called p53. This protein is a well-known tumor suppressor that helps to prevent the growth and spread of cancer cells.

In addition, the RORA gene has also been shown to be involved in the regulation of cell differentiation. This is important because the regulation of cell differentiation is a critical process that is involved in the development and maintenance of tissues and organs.

The potential clinical applications of the RORA gene as a drug target or biomarker are vast. For example, it could be used to treat a variety of diseases, including cancer, obesity, and diabetes.

The potential drug targets for the RORA gene are numerous. One of the most promising targets is the use of the RORA gene to treat cancer. Studies have shown that inhibiting the production of p53, the tumor suppressor protein, can be an effective way to treat cancer. This is because p53 is a critical protein that is involved in the regulation of cell survival, and inhibiting its production can result in the growth and spread of cancer cells.

Another promising application of the RORA gene as a drug target is its potential to treat obesity. Obesity is a serious health problem that is associated with a range of diseases, including heart disease, diabetes, and certain cancers. The RORA gene has been shown to be involved in the regulation of cell size and body weight, which makes it an attractive target for drugs that are designed to reduce body weight.

In addition, the RORA gene has also been shown to be involved in the regulation of cell survival and differentiation, which makes it an attractive target for drugs that are designed to promote cell death or promote the growth and development of cancer cells.

The potential biomarker for the RORA gene

The RORA gene has also been identified as a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the regulation of cell growth and differentiation, which makes it an attractive target for biomarkers that are designed to reflect these processes.

In addition, the RORA gene has also been shown to be involved in the regulation of cell survival, which makes it an attractive target for biomarkers that are designed to reflect the

Protein Name: RAR Related Orphan Receptor A

Functions: Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development (PubMed:29656859). Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction. Regulates the circadian expression of several clock genes, including CLOCK, BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes. In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC1 and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms. May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling

The "RORA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RORA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets